Andere talen Apollomics, Inc.

Aandelen

APLM

KYG0411D1079

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3719 ^USD	-6,23%		-6,20%	-61,46%

08/05	Apollomics, Inc. Benoemt Robert (Bob) Lin tot lid van de Raad van Bestuur	CI
25/04	Avistone Biotechnology Co. Ltd. Ontvangt goedkeuring van de National Medical Products Administration van China voor Vebrelinib (APL-101) voor de behandeling van gliomen met Met fusiegenen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics Announces Private Placement Financing and Addition to Board of Directors	08/05
Apollomics, Inc. Appoints Robert Lin to the Board of Directors	08/05
Apollomics, Inc. announced that it has received $5.75 million in funding	08/05
Apollomics, Inc. announced that it expects to receive $5.75 million in funding	06/05
Apollomics : April 2024 Corporate Presentation	25/04
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	25/04
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene	25/04
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	10/04
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	05/04
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	02/04
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	28/03
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	26/03
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	04/03
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer	04/03
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Apollomics, Inc.

Aandelen

APLM

KYG0411D1079

Andere talen

Filters